Antibody Therapy for Patients with Lymphoid Malignancies: Past and Present

被引：0
|
作者：
Naman, Jacob [1 ]
Shah, Nirja [2 ]
Heyman, Benjamin M. [3 ]
机构：
[1] UC San Diego Hlth, Dept Med, La Jolla, CA 92037 USA
[2] UCSD, Sch Med, La Jolla, CA 92037 USA
[3] UC San Diego Hlth, Div Regenerat Med, Dept Med, La Jolla, CA 92037 USA
来源：
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | 2025年 / 26卷 / 04期
关键词：
antibody; malignancy; CLL; FL; DLBCL; rituximab; obinutuzumab; polatuzumab; mosunetuzumab; epcoritamab; CHRONIC LYMPHOCYTIC-LEUKEMIA; ANTI-CD20; MONOCLONAL-ANTIBODY; PHASE-II TRIAL; MAGROLIMAB PLUS RITUXIMAB; LOW-TUMOR BURDEN; FOLLICULAR LYMPHOMA; OPEN-LABEL; LONCASTUXIMAB TESIRINE; BRENTUXIMAB VEDOTIN; 1ST-LINE TREATMENT;
D O I：
10.3390/ijms26041711
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Antibody therapies are a crucial component of modern lymphoid malignancy treatment and an exciting area of active research. We performed a review of modern antibody therapies used in the treatment of lymphoid malignancies, with an emphasis on landmark studies and current directions. We describe the indications for rituximab, obinutuzumab, ADCs, and bispecific antibody therapies. Finally, we summarize early data from ongoing trials on emerging novel therapy combination regimens and discuss the role of machine learning in future therapy development.
引用
收藏
页数：21
相关论文
共 50 条
  • [31] Towards molecular diagnosis and targeted therapy of lymphoid malignancies
    Wiestner, A
    Staudt, LM
    SEMINARS IN HEMATOLOGY, 2003, 40 (04) : 296 - 307
  • [32] Cellular Mechanisms Regulating CD20 As a Target of Monoclonal Antibody Therapy in B-Lymphoid Malignancies
    Smida, Michal
    Kozlova, Veronika
    Vakulova, Viera
    Ledererova, Aneta
    Doubek, Michael
    Mayer, Jiri
    Pospisilova, Sarka
    BLOOD, 2016, 128 (22)
  • [33] Past, Present, and Future Management of Localized Biliary Tract Malignancies
    Li, Janet
    Rocha, Flavio G.
    Mayo, Skye C.
    SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA, 2023, 32 (01) : 83 - 99
  • [34] Resilience in patients with lymphoid malignancies: The REPLY study
    dos Santos, Gimena
    Bogliacino, Vanesa
    Irigoin, Victoria
    Guillermo, Cecilia
    ANNALES MEDICO-PSYCHOLOGIQUES, 2025, 183 (02): : 129 - 135
  • [35] Development of a novel antibody-drug conjugate for refractory lymphoid malignancies
    Arita, Daigo
    Saijho, Sinji
    Matsumura, Yasuhiro
    Yasunaga, Masahiro
    CANCER SCIENCE, 2018, 109 : 389 - 389
  • [36] Antibody drug conjugates as targeted cancer therapy: past development, present challenges and future opportunities
    Maiti, Ritwik
    Patel, Bhumika
    Patel, Nrupesh
    Patel, Mehul
    Patel, Alkesh
    Dhanesha, Nirav
    ARCHIVES OF PHARMACAL RESEARCH, 2023, 46 (05) : 361 - 388
  • [37] Past, Present, and Future of Rituximab-The world's First Oncology Monoclonal Antibody Therapy
    Pierpont, Timothy M.
    Limper, Candice B.
    Richards, Kristy L.
    FRONTIERS IN ONCOLOGY, 2018, 8
  • [38] Surfactant therapy: past, present and future
    Speer, Christian R.
    Sweet, David G.
    Halliday, Henry L.
    EARLY HUMAN DEVELOPMENT, 2013, 89 : S22 - S24
  • [39] Grid therapy: past, present, and future
    Siegbahn, A.
    RADIOTHERAPY AND ONCOLOGY, 2017, 123 : S213 - S214
  • [40] ANTITHROMBOTIC THERAPY (PAST, PRESENT AND FUTURE)
    OWEN, CA
    KLINICHESKAYA MEDITSINA, 1984, 62 (01): : 14 - 17
12345